RIG-I ligand enhances the immunogenicity of recombinant H7HA protein

• Type of Material: Article
• Authors: Weiping Cao, Centers for Disease Control and Prevention; Justine Liepkalns, Emory University; Ram P. Kamal, Centers for Disease Control and Prevention; Adrian J. Reber, Centers for Disease Control and Prevention; Jin Hyang Kim, Centers for Disease Control and Prevention; Amelia R. Hofstetter, Centers for Disease Control and Prevention; Samual Amoah, Centers for Disease Control and Prevention; James Stevens, Centers for Disease Control and Prevention; Priya Ranjan, Centers for Disease Control and Prevention; Shivaprakash Gangappa, Emory University; Ian A. York, Centers for Disease Control and Prevention; Suryaprakash Sambhara, Centers for Disease Control and Prevention
• Language: English
• Date: 2016-04-09
• Publisher: Elsevier
• Publication Version: Author Accepted Manuscript (After Peer Review)
• Copyright Statement: © 2017 Elsevier B.V. or its licensors or contributors.
• License: Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1016/j.cellimm.2016.04.004
• Title of Journal or Parent Work: Cellular Immunology
• ISSN: 0008-8749
• Volume: 304
• Start Page: 55
• End Page: 58
• Grant/Funding Information: Work was supported by the Influenza Division, Centers for Disease Control and Prevention.
• Keywords: INFLUENZA-VIRUS; Protective immunity; Life Sciences & Biomedicine; Immunology; H5N1; PANDEMIC INFLUENZA; Cell-mediated immunity; VACCINE; Mouse model; ACTIVATION; Antibody responses; Science & Technology; Influenza; INNATE IMMUNITY; INFECTION; RIG-I ligand; PHASE-I; Cell Biology; H7HA
• Research Categories: Health Sciences, Pathology; Health Sciences, Immunology

Abstract

Avian H7N9 influenza virus infection with fatal outcomes continues to pose a pandemic threat and highly immunogenic vaccines are urgently needed. In this report we show that baculovirus-derived recombinant H7 hemagglutinin protein, when delivered with RIG-I ligand, induced enhanced antibody and T cell responses and conferred protection against lethal challenge with a homologous H7N9 virus. These findings indicate the potential utility of RIG-I ligands as vaccine adjuvants to increase the immunogenicity of recombinant H7 hemagglutinin.